We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

4,200
Open access books available

116,000
International authors and editors

125M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Chapter 17

Evolvement of microRNAs as Therapeutic Targets for Malignant Gliomas

Sihan Wu, Wenbo Zhu and Guangmei Yan

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/52672

1. Introduction

Malignant glioma (MG), consisting of anaplastic glioma (AA, WHO grade III) and glioblastomamultiforme (GBM, WHO grade IV, 60-70%), is the most common and destructive brain tumor [1]. Despite systemic treatment, surgical resection followed by radiotherapy and chemotherapy, the prognosis of patients with GBM remains poor with a median survival of 12 to 15 months and a 5-year survival rate of 9.8% [2, 3]. The dismal outcome fuels the need to understand the molecular basis of gliomagenesis and identify novel therapeutic targets for MG treatment.

With a developing understanding of core aberrant signaling pathways in MG, molecular targeted therapy has shown certain promise as a more rational strategy. Established targets, including receptor tyrosine kinases (RTK) such as EGFR, PDGFR and VEGFR, as well as mTOR, farnesyl transferase and PI3K, have drawn particular interests both in fundamental and clinical research. However, single targeted agents so far have not displayed desirable clinical outcomes as expected, with response rates of 0 to 15% and no prolongation of 6-month progression-free survival [4–6]. This disappointing outcome is primarily due to the nature of cancer with multi-genetic abnormality and inter/intra-tumor heterogeneity. Therefore, multiple targeting strategies are essential to achieve better clinical benefits.

MicroRNA (miRNA), a type of endogenous small non-coding RNA which negatively modulates gene expression in post-transcriptional level, has rapidly become a topical issue since it was firstly discovered in C. elegans two decades ago[7]. Increasing researches have reported that dysregulation of miRNA is closely associated with tumorigenesis and tumor progression. In gliomas, a group of miRNAs have been characterized as oncogenic and tumor-suppressive molecules. With a unique feature of multi-targeting, miRNA may become a new powerful weapon fighting against MG. Although much remains to be learned about formu-
lating miRNAs as nucleic acid drugs, we feel that identification of miRNAs as therapeutic targets for gliomas is now within sight.

In this chapter, we will critically review issues relevant to contemporary researches on miRNAs and MG. Based upon other teams’ and our data, this review will present findings on onocgenic and tumor-suppressive properties of miRNA in MG, focusing on the mechanisms of dysregulation, the involvement with core pathways of MG and the functional heterogeneity in different context. Besides, we will formulate evidences for miRNA-based clinical application in diagnosis and therapeutics of MG. The developing cognition of miRNAs will ultimately lead to innovative clinical approaches for MG.

2. Oncogenic and tumor-suppressive miRNAs in malignant gliomas

The very first oncogenic miRNA indentified in GBM is miR-21 as early as 2005 [8], although whose target genes were not fully understood at that time. In 2008, another group identified a set of targets of this miRNA which constitute a tumor-suppressive network including TGF-β, p53 and mitochondrial-apoptotic pathways [9]. This is one of the examples showing the multi-targeting nature of miRNAs in oncology. Beyond multi-targeting, these findings also prompt a hypothesis that miRNAs may have pathway preference in some cases.

Coincidently, also in 2005, S.A. Ciafre et al. firstly described that brain-enriched miR-128 and miR-181 family were frequently down-regulated in primary GBMs and cell lines [10], whose tumor-suppressive roles of these miRNAs were subsequently validated in the next few years [11–14].

In 2008, a milestone has been made in glioma research, accomplished by The Cancer Genome Atlas (TCGA) Research Network. Through integrative analysis of DNA copy number, gene expression and DNA methylation aberrations, TCGA defined three major pathways in GBM, which are RTK, p53 and RB signaling pathways, as shown in Figure 1 [15]. These pathways cannot be more familiar to every oncologist: frequently activated RTK signaling in cancer supports cell proliferation and survival, whereas p53 and RB signaling monitor cell cycle transition and couple to apoptosis and senescence pathways, which are commonly suppressed in cancer. To date, increasing oncogenic and tumor-suppressive miRNAs in MGs have been uncovered. In combination with genomic sketch of GBM described by TCGA, we have a deeper insight into the interactions within the core pathways of MG, which are controlled in coding and non-coding levels (Figure 1).

Here we do not pay our attention to the detail of each single miRNA, since several reviews have provided considerable details about their expression and function [16–18]. In this paper, we prefer to focus on how these miRNAs become aberrant, and which malignant phenotypes they contribute to.

As well as every protein coding gene, non-coding miRNA genes may similarly undergo over or lost expression, amplification, deletion, insertion, translocation and mutation, which lead to aberration of miRNAs. The mechanisms of miRNA aberration have not yet been ex-
tensively studied. Nevertheless, there have been some clues showing that transcriptional activity, single nucleotide polymorphism (SNP) and chromosome deletion contribute to aberrant genotype and malignant phenotype of MG.

The most interesting research addressing miRNA transcriptional regulation machinery in MGs is the TP53 and miR-25/32 feedback circuitry [19]. Carlo M. Croce’s and co-workers found that miR-25 and miR-32 are negatively regulated by TP53 via repressing their transcriptional factors MYC and E2F1. Intriguingly, by directly targeting MDM2 and TSC1, these miRNAs help stabilize P53 protein and suppress tumorigenicity in U87 GBM cells. Thus, a fine tuned recurrent autoregulatory circuit form. However, in the non-functional mutant TP53 context, miR-25/32 support cell proliferation per contra. These findings not only provide insights into the interaction between miRNAs and TP53 tumor-suppressive pathway, but also hint that a given miRNA may have distinct function in different genetic and biochemical status.

It is unexpected that miRNA genes rarely exhibit SNP or mutation within the major mature sequence segment, although which can be commonly found in the precursor (including the minor mature sequence which is formerly called the star sequence) and primary miRNA segments. Through mining human SNP database, Peng Jin’s group identified a G>U polymorphism located in the eighth nucleotide of the mature miR-125a-5p. The U allele blocks the processing from pri-miRNA to miRNA precursor by altering the secondary structure, and impairs miRNA-mediated translational suppression [20]. MiR-125s have been demonstrated to be tumor-suppressive in GBM [21–23]. However, such nucleotide alteration has not yet been described in glioma clinical data. The rs11614913 SNP, which locates in the segment producing minor mature miR-196a-3p (termed miR-196a* previously), was firstly found to be associated with the risk of glioma in Chinese population [24]. Recent clinical study indicates that the rs2910164 in segment containing minor mature miR-146a-3p sequence is also relative to the risk and prognosis in adult glioma [25]. These findings improve our understandings of miRNA-related pathogenesis and diagnostics in gliomas. Further research is required to fully comprehend the exact mechanisms underlying the relationship between miRNA gene SNPs and clinical outcomes, which may have huge clinical potential.

Chromosome alteration undoubtedly contributes to miRNA aberration. Particularly in diffuse astrocytoma (DA, WHO II) and AA, chromosome 7q32 is a hotspot that frequently amplifies. This region embraces eight miRNAs: miR-593, miR-129-1, miR-335, miR-96, miR-183, miR-29a and miR-29b-1. Among these miRNAs, our group recently reported that miR-335 is the most striking target in AA [26]. We have demonstrated that miR-335 confers invasive and proliferative malignant phenotype on astrocytoma via targeting DAAM1. Disrupting miR-335 by cholesterylated miRNA inhibitor abrogates invasion and elicits apoptosis both in vitro and in vivo. Chromosome amplification in cancer often creates abnormal high level of coding and non-coding products that subsequently infests the well-balanced signaling. Currently, drug screening and discovery in oncology specifically focus on over-expressed protein and over-activated kinase. We believe that miRNA, such as miR-335, may also be the target for drug development in the future.
In the last session we have mentioned that miR-25/32 functions differently depended on TP53 status in GBM. It is not the sole evidence that a given miRNA plays distinct roles in respective models. In fact, miRNAs show complicated functional heterogeneity. One of the examples is miR-135a/b. Remco Nagel et al. found increased expression levels of miR-135a and miR-135b during colorectal cancer progression, which target the tumor suppressor gene Adenomatous Polyposis Coli (APC)[27]. The oncogenic role of miR-135a was further confirmed by BR Zetter’s group. They demonstrated that paclitaxel resistance is associated with up-regulation of miR-135a in multiple solid tumor cell lines. Knocking-down of miR-135a acquires susceptibility to paclitaxel[28]. However, in classic Hodgkin lymphoma (cHL), miR-135a directly regulates JAK2, thus suppressing the expression of BCL2L1 (also known as BCL-XL) and inducing apoptosis. Furthermore, higher level of miR-135a indicates better disease-free survival in cHL patients [29]. Likewise our group has also characterized that miR-135a functions as a selective killer of MG. We have reported that glial cell-enriched miR-135a is frequently down-regulated in MG and negatively correlates with
the pathological grading of gliomas. Ectopic delivery of miR-135a selectively triggers mitochondrial dependent apoptosis in MG in vitro and in vivo. Interestingly, this lethal effect is neutral in normal glial cells and neurons [30].

MiR-335 gives us another example of the dual role nature of miRNAs. An early study identified that miR-335 suppresses breast cancer metastasis and migration through targeting SOX4 and TNC [31]. However, as mentioned above, our recent research found that this miRNA promotes invasion and proliferation in AA [26]. In this way, miRNAs seems to have cell-type-dependent functional heterogeneity. The definition of “tumor-suppressive” and “oncogenic” should be carefully employed depended on the cell types and diseases.

Even within the same cell type, the functional behavior of a given miRNA can also be diverse. Previously we have reported that activation of cAMP/PKA pathway, manipulated by Cholera toxin, induces cellular differentiation of MG, showing malignant phenotype reversion and potent GFAP (glial fibrillary acidic protein) expression [32]. As it has been well characterized, we found that IL-6/JAK2/STAT3 contributes to GFAP expression in this model [33]. Notably, epigenetic mechanism is also involved. In this context, the so-called oncogenic miR-335 in MG induced by Cholera toxin enhances GFAP expression in MG cell lines and primary cultures [34]. Multi-targeting is one of the natures of miRNAs. Signaling networks composed of target genes and their relative molecules may both contribute to tumor-suppressive and oncogenic function. It seems that the oncogenic functions of miR-335 are hindered under a high endogenous level of cAMP, rewiring to pro-differentiation pathways.

To sum up, the role of a given miRNA depends on the script which is assigned by the cell type, the genomic context and in part the cellular biochemical status. These observations re-mind that disease state as well as the genomic subclass of MGs should be considered in the preclinical study especially for drug discovery involved miRNAs.

4. Involvement of miRNAs as novel biomarkers in malignant gliomas

Biomarkers are distinctive biological indicators that serve for diagnosis, prognosis and medication. Traditional biomarkers include mRNAs, proteins and metabolites. At present, miRNAs are emerging as novel and practical biomarkers in oncology. Due to their surprising stability, miRNAs can not only be detected in fresh and frozen tissues, but also in body fluids and even formalin-fixed paraffin-embedded samples. In the study of Roland Schroers, miR-15b and miR-21 are found in cerebrospinal fluid and demonstrated to be markers of glioma [35]. Although much remains to be studied, e.g. to discover more accurate and specific markers for respective glioma types, this finding provides a new opportunity to develop less invasive and early diagnostic approach for gliomas.

Besides diagnosis, miRNAs may be promising biomarkers for prognosis. Jun Li’s group has reported that miR-182 is markedly up-regulated in various glioma cell lines and primary glioma specimens. Furthermore, higher level of miR-182 is associated with poor overall survival of patients with malignant glioma [36]. A more comprehensive study was recently car-
ried out by Sujaya Srinivasan, et al. They analyzed miRNA expression profile of GBM patients (n = 222) from TCGA database and found a ten-miRNA expression signature that predicts survival for GBM. In detail, three miRNAs (miR-20a, miR-106a and miR-17-5p) were identified as protective markers and seven miRNAs (hsa-miR-31, hsa-miR-222, hsa-miR-148a, hsa-miR-221, hsa-miR-146b, hsa-miR-200b and hsa-miR-193a) were risky [37].

Recent studies have raised a possibility that miRNAs may function as predictive markers for therapeutics. Temozolomide (TMZ) is a well-known alkylating agent against gliomas, which methylates guanines in the O-6 position. Accumulating O-6 methyl guanines lead to DNA mismatch during replication and ultimately result in cell death. Although MGMT (methyl-guanine methyl transferase) promoter methylation has been proved to be a strongest marker to predict the TMZ response in low-grade and high-grade gliomas [38–40], it may not be the only indicator. Recent research indicates that miR-181b/c, miR-195, miR-455-3p and miR-10a-3p, rather than MGMT promoter methylation, predict response to concomitant chemoradiotherapy and acquired TMZ resistance in GBM cell line and patients [41, 42]. In addition, increasing evidences indicate that miRNAs also contribute to other drug response. For instance, up-regulated miR-21 confers teniposide and paclitaxel resistance on GBM cells [43, 44]. Various highly efficient MGMT inhibitors have been developed for sensitizing tumor to TMZ [45]. The emerging roles of miRNAs in drug resistance of TMZ and other antineoplastic agents give us a novel angle to include miRNAs as therapeutic targets.

5. Perspectives on miRNAs as nucleic acid drugs in malignant gliomas

5.1. MiRNAs replacement therapy and suppressive therapy

Human body has an extremely complicated internal environment, relying on balance and stability of which human keep their health. Once the homeostasis is disrupted by down-regulation or up-regulation of some important molecules including miRNAs, human will suffer from all kinds of diseases. Based on the disequilibrium status, the ideal protocols to cure diseases are believed to replace what is lost and to repress what is excessive, which are respectively called replacement therapy and suppressive therapy. For the former, estrogen replacement therapy is the most representative example, which is generally used in menopausal women with menopausal syndrome caused by ovarian hormones loss and has shown a positive effect [46]. For the latter, a typical case is a famous anti-angiogenesis drug Avastin, the humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody for cancer therapy [47]. Besides, Gefitinib and Glivec specially inhibiting EGFR tyrosine kinase, have both achieved high clinical benefit rates in treating cancer especially lung carcinoma and chronic myelocytic leukemia[48,49], further indicating the efficacy of suppressive therapy via targeting core molecules in tumorigenesis.

Notably, increasing evidences demonstrated that gliomagenesis is also closely associated with deregulation of miRNAs, such as up-regulation of oncogenic miRNAs and down-regulation of tumor suppressive miRNAs. Therefore, targeting these aberrant miRNAs has tremendous potential as a therapeutic strategy by down- or up-regulating altered genes.
Specially, miRNA mimics can be synthesized to replace lessened ones critical in gliomagenesis, and miRNA inhibitors can be designed to suppress the function of up-regulated oncogenic miRNAs. Just less than two decades after discovering the role of miRNAs in oncology, the replacement and suppressive therapies of miRNA are already being used in preclinical researches. We have proved that artificially rectification of abnormally expressed miRNAs inhibited growth of glioma xenografts in mice and prolonged the median survival of rat with orthotopic glioma\cite{26,30}, opening a new sight for glioma treatment.

5.2. MiRNA-targeting cocktail therapy

Glioma is a complicated disease of altered genes. TCGA has reported multiple chromosomal aberrations, nucleotide substitutions and epigenetic modifications that construct three core pathways (as shown in Figure 1) \cite{15}. Furthermore, glioma is a disease of altered miRNAs. A genome-wide expression profiling of 26 GBMs, 13 AAs and 7 normal brain samples identifies multiple deregulated miRNAs in MGs \cite{50}. In addition, large scale of sequencing analysis of GBMs has identified extensive genetic heterogeneity between GBM samples from different patients \cite{51}, implying the possibility of miRNA’s heterogeneity. The multiplicity of deregulated miRNAs and the heterogeneity of deregulated miRNAs expression profiling may foster therapeutic failure and tumor adaptation to solo miRNA-targeting therapy.

To date, researchers just verified the efficiency of targeting solo miRNA as if by prior agreement. What will happen if target several pivotal miRNAs simultaneously? Given the multiplicity of deregulated miRNAs in glioma, a cocktail consisting of special miRNA mimics and/or inhibitors may kill multiple birds with one stone. In another word, components in cocktail may have an additive effect or even a synergistic effect against MGs. Furthermore, considering individual differences, one cocktail may not fit for each patient with MGs. If we can design a specific miRNA cocktail based on individual deregulated miRNAs, miRNA individualized treatment will be within our sights. Certainly, additional preliminary evidences are needed to verify the feasibility and availability of miRNA-targeting cocktail therapeutics.

5.3. Engineering miRNA

Engineering miRNA (emiRNA) is artificially designed in sequence, endowed with functional similarity to natural miRNA and functional specificity according to human’s will. In a sense, emiRNA is a branch of small interfering RNA (siRNA) that possesses multi-targeting power just as natural miRNA.

Leastwise, there are two strategies to design emiRNA: (a) adjustment based on the natural miRNA sequence; (b) de novo design.

In the sessions above, we have discussed the fact that a given miRNA may play distinct role in different models, e.g. different genetic background, different cell type and different second messenger level. Even in a “conclusive” circumstance that a certain miRNA strongly kills a type of cancer cell, we still need to evaluate its pharmacodynamics in the cancer tissue and toxic side effect to the normal tissue before clinical application. If a natural sequence
miRNA shows remarkable antitumor effect but exhibits unsatisfying selectivity, does it mean we should totally abandon this target? The problem may be solved by emiRNA technology. Different dominant target genes and their roles in different models determine the functional heterogeneity of a given miRNA. If we are able to find out the undesired targets that lead to unsatisfying selectivity, perhaps by keeping the seed region of the miRNA and adjusting its 3’ nucleotide sequence, we could either avoid the interaction between the miRNA and the undesired target genes, or enhance the binding to our goal targets.

In broader context, we could design an artificial miRNA in a de novo way. Cancers are known as a type of multigenic disease. By comprehensive sequencing, RTK/RAS/PI3K, p53 and RB signalings are characterized as the core pathways in GBM [15]. In virtue of bioinformatics, it is possible to design a miRNA that contemporaneously targets the key components of two or more pathways by carefully examining their mutual microRNA recognition elements (MREs).

However, numbers of scientific problems need to be addressed before putting emiRNA into practice. We still have limited knowledge about the details of miRNA biogenesis and the MRE language passing on along evolution. Someday the secret will be unlocked and emiRNA may be a practical weapon against cancers.

5.4. MiRNA formulation

Another attractive issue of translating miRNA into clinical application is formulation. Although whose length is quite short in the RNA world, miRNA as well as siRNA is a type of high molecular weight drug in pharmaceutical point of view. Additionally, electric charge contributed by phosphate groups of the nucleic acid backbone make it inadequate for CNS delivery. Fortunately, new technical progress brings miRNA formulation within sight.

In the earlier period, viral vector including retrovirus, adenovirus, herpes simplex virus and adeno-associated virus were broadly used due to their high efficiency for both gene delivery and expression. However, limitations associated with safety, genomic stability and immunogenicity motivate scientists to focus on non-viral systems. At present, remarkable achievements have been made in chemical modifications and conjugations of small RNA. For example, locked nucleic acid (LNA) technology not only increases melting temperature of RNA-RNA duplex thus enhancing the binding affinity between small RNA and target transcript, but also improves the half-life of small RNA in serum, which is critical for therapeutic use [52]. Cholesterylation, viz. modification with cholesteryl functionality, which improves the cellular uptake of small RNA, is now extensively used for miRNA mimics/inhibitors and siRNA in preclinical research [53]. Two reviews have provided clear and comprehensive introduction of the progress on chemical small RNA encapsulation [54, 55]. Particularly, a recent study from Paula Hammond and colleagues reported a self-assembled microparticles of small RNA hairpin polymersin incorporated more than half a million copies of siRNA in a single nanoparticle [56]. This novel technology allow one thousand times lower concentration to achieve same degree of gene silencing efficiency as conventional strategies, showing great clinical application potential. In the near future, small RNA formulation will further benefit from evolution of nanotechnology and biomaterial technology.
6. Concluding remark

Glioma is not the type of high incidence disease; however the depressive clinical outcomes still threaten human health. Special location, rapid proliferation, invasive growth and massive angiogenesis are the key issues that limit treatment for MG. In addition, extremely complicated histopathological and genomic classifications perplex fundamental and clinical research.

With the evolution of new generation high through-put sequencing technology, clearer insights of driver mutations and core pathways in various cancers are gradually revealed in the recent period [57–59]. According to these cancer genomic studies, we realize that not only aberrant coding genes lead to cancers, but also non-coding components underneath the iceberg. Twenty-year’s research on miRNA opens a new world of genetics and oncology. More and more groups are dedicated to study the role of miRNA in cancer including glioma. Albeit fragmentary, accumulating data will offer deeper insights of glioma with more systematic considerations.

Compared with other non-coding protagonists, e.g. histone modification and DNA methylation, miRNA is the easiest role to be specifically manipulated, either by over-expression or inhibition, which determines miRNA to be the star with enormous clinical potential. Although we have not drawn an elaborate picture of miRNA biogenesis, especially how primary sequence and intra-cellular microenvironment influence secondary structure and eventually contribute to processing and maturation, as well as the communication principles between miRNA and MRE, we believe that technologies nowadays are poised to uncover the law of miRNA in oncology. We envision that this intrinsic biomolecule will be the therapeutic target for cancer.

Author details

Sihan Wu, Wenbo Zhu and Guangmei Yan
Zhongshan School of Medicine, Sun Yat-sen University, People’s Republic of China

References


